期刊文献+

阿立塞替通过靶向Aurora激酶A提高人非小细胞肺癌细胞的放射敏感性 被引量:1

Study on Alisertib Enhancing Radiosensitivity of Human Non-small Cell Lung Cancer Cells by Targeting Aurora Kinase A
下载PDF
导出
摘要 目的:探讨阿立塞替(MLN8237)对人非小细胞肺癌放射敏感性的影响及作用机制。方法:用siPORT NeoFX转染试剂将阴性siRNA、si Aurora Kinase A分别转染NCI-H1975细胞阴性对照组(Si control)及靶向Aurora激酶A组(si Aurora Kinase A),未转染siPORT NeoFX的NCI-H1975细胞作为单纯对照组(Control);CCK8实验检测抑制Aurora激酶A的抑制剂(MLN82370)对NCI-H1975细胞生长的影响,细胞凋亡实验检测抑制Aurora激酶A及加入MLN8237对NCI-H1975细胞凋亡的影响,克隆形成实验检测了MLN8237对NCI-H1975细胞放射敏感性的影响影响,qRT-PCR实验评估了NCI-H1975细胞中p16及p21的表达,荧光素酶分析实验测定细胞周期相关转录因子(E2F)和应激活化蛋白激酶(JNK)的活性。结果:NCI-H1975细胞的转染效率达89.91%,抑制Aurora激酶A及加入MLN8237可明显抑制NCI-H1975细胞的生长,差异有统计学意义(P<0.01);细胞凋亡实验结果显示,抑制Aurora激酶A及加入MLN8237可明显提高NCI-H1975细胞的凋亡率;克隆形成实验显示,MLN8237能够显著降低照射后NCI-H1975细胞的克隆形成能力对NCI-H1975细胞有放射增敏效果,且随剂量增大其增敏效果越显著;qRT-PCR结果显示,加入MLN8237(Aurora激酶A抑制剂)照射后,p16及p21的表达明显上调;荧光素酶分析实验结果显示,抑制Aurora激酶A显著降低了E2F的活性,而JNK的活性显著提高,差异均有统计学意义(P<0.01)。结论:阿立塞替能通过靶向Aurora激酶A,而抑制NCI-H1975细胞增殖及诱导其凋亡,从而提高NCI-H1975细胞的放射敏感性。 Objective:To investigate the effect of alisertib on the radiosensitivity of human non-small cell lung cancer by targeting Aurora kinase A.Methods:NCI-H1975 cells were transfected with siPORT NeoFX transfection reagent and divided into Si control group,Si Aurora Kinase A group;Nci-H1975 cells that were not transfected with siPORT NeoFX were used as the control group.The effects of inhibitors that inhibit Aurora kinase A(MLN82370)on NCI-H1975 cells growth were detected by CCK8 assay;the effects of Aurora kinase A inhibition and the addition of MLN8237 on the apoptosis of NCI-H1975 cells were detected by apoptosis assay;the effects of MLN8237 on radiosensitivity of NCI-H1975 cells were examined by cloning formation experiment;the expression of p16 and p21 in NCI-H1975 cells was evaluated by qRT-PCR;the activities of E2F and JNK were determined by luciferase assay.Results:The transfection efficiency of NCI-H1975 cells was 89.91%;CCK8 results showed the growth of NCI-H1975 cells were significantly inhibited by Aurora kinase A or adding the MLN8237,the difference was statistically significant(P<0.01).The results of apoptosis assay showed the apoptosis of NCI-H1975 cells were significantly increased by inhibiting of Aurora kinase A or adding MLN8237;The cloning formation experiments showed the cloning forming ability of NCI-H1975 cells were significantly reduced with MLN8237 after irradiation,the radiosensitivity of NCI-H1975 cells were significantly increased with MLN8237;The qRT-PCR results showed the expression of p16 and p21 was significantly up-regulated after IR with MLN8237(Aurora kinase A inhibitor);The results of Luciferase analysis showed that the activity of E2F was significantly decreased while the activity of JNK was significantly increased by inhibition of Aurora kinase A(P<0.01).Conclusion:Alisertib can inhibit the proliferation and induce apoptosis of NCI-H1975 cells by targeting Aurora kinase A,thereby increasing the radiosensitivity of NCI-H1975 cells.
作者 李舜 杨智松 韩国征 李红艳 齐浩明 LI Shun;YANG Zhisong;HAN Guozheng;LI Hongyan;QI Haoming(Daqing Longnan Hospital,Daqing 163000,Heilongjiang,China;Department of Traditional Chinese Medicine,the First Affiliated Hospital of Shihezi University,Shihezi 832008,Xinjiang,China;Department of Cardiovascular Medicine,Weinan Central Hospital,Weinan,714000 Shaanxi,China)
出处 《贵州医科大学学报》 CAS 2020年第5期531-538,共8页 Journal of Guizhou Medical University
基金 国家自然科学基金项目(31560270)。
关键词 非小细胞肺 转染 辐射耐受性 细胞凋亡 细胞增殖 阿立塞替 carcinoma non-small-cell lung(NSCLC) transfection radiation tolerance apoptosis cell proliferation alisertib
  • 相关文献

参考文献1

二级参考文献46

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA-Cancer J Clin,2011,61 (2) :69 - 90.
  • 2Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [ J ]. N Engl J Med, 2004, 350(21 ):2 129 -2 139.
  • 3West L, Vidwans S J, Campbell NP,et al. A novel classification of lung cancer into molecular subtypes [ J ]. PloS ONE, 2012,7 (2) : e31906.
  • 4Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor speeiroens from 1,000 patients with lung adenocarcinoma: the NCI's Lttng Cancer Mutation Consortium ( LCMC ) [ J ]. J Clin 0ncol,2011,29 ( Suppl 18 ) : CRA7506.
  • 5Broad I, Hammerman PS, Lawrence MS, et al. Comprehensive genomic characterization of squamous cell lung cancers [ J ]. Nature,2012,489(7 417) :519 -525.
  • 6Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[ J]. N Engl J Med,2004, 350(21) :2 129 -2 139.
  • 7Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combina- tion with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1 [ J ]. J Clin Oncol, 2004,22(5) :777 -784.
  • 8Mok TS, Wu YL,Thongprasert S,et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009,361(10) :947 -957.
  • 9Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL,CTONG-0802) : a multicentre, open-label, randomised, phase 3 study [ J ]. Lancet Oncol,2011,12(8 ) :735 -742.
  • 10Yun CH, Mengwasser KE,Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[ J]. Proc Natl Acad Sci U S A,2008,105(6) :2 070 - 2 075.

共引文献27

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部